Gsk Plc Stock Retained Earnings
| GLAXF Stock | USD 16.83 0.21 1.23% |
GSK plc fundamentals help investors to digest information that contributes to GSK Plc's financial success or failures. It also enables traders to predict the movement of GSK Pink Sheet. The fundamental analysis module provides a way to measure GSK Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GSK Plc pink sheet.
GSK |
GSK plc Company Retained Earnings Analysis
GSK Plc's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current GSK Plc Retained Earnings | (6.55 B) |
Most of GSK Plc's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GSK plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, GSK plc has a Retained Earnings of (6.55 Billion). This is 803.27% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The retained earnings for all United States stocks is 170.21% higher than that of the company.
GSK Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GSK Plc's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GSK Plc could also be used in its relative valuation, which is a method of valuing GSK Plc by comparing valuation metrics of similar companies.GSK Plc is currently under evaluation in retained earnings category among its peers.
GSK Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X | |||
| Price To Sales | 1.91 X | |||
| Revenue | 29.32 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.8 B | |||
| Net Income | 14.96 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Current Ratio | 1.43 X | |||
| Book Value Per Share | 2.63 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 1.32 X | |||
| Price To Earnings To Growth | 1.11 X | |||
| Number Of Employees | 45 | |||
| Beta | 0.28 | |||
| Market Capitalization | 73.5 B | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (6.55 B) | |||
| Working Capital | (525 M) | |||
| Current Asset | 17.61 B | |||
| Current Liabilities | 18.14 B | |||
| Z Score | 1.8 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 5.36 % | |||
| Net Asset | 60.15 B | |||
| Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.